Day: January 4, 2024

EVANSVILLE, Ind., Jan. 04, 2024 (GLOBE NEWSWIRE) — (NASDAQ: ONB) – Old National Bancorp, the holding company of Old National Bank, today announced the following schedule for its fourth-quarter and full-year 2023 earnings release and conference call:Earnings Release:       Tuesday, January 23, 2024, at approximately 8:00 A.M. ET     Conference Call:   Tuesday, January 23, 2024, at 10:00 A.M. ET     Dial-in Numbers:   U.S. (888) 300-3045; International: (646) 568-1027; Access code 5258325     Webcast:   Via Old National’s Investor Relations website at oldnational.com     Webcast Replay:   Available approximately one hour after completion of the call, until midnight ET on January 23, 2025, via Old National’s Investor Relations website at oldnational.com     Telephone Replay:   U.S. (800) 770-2030;...

CORAL GABLES, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) announced today that it has commenced an underwritten public offering of $150,000,000 of its common stock. Catalyst also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering, at the public offering price, less underwriting discounts. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. All of the shares in the offering are being sold by Catalyst. BofA Securities, Citigroup, Piper Sandler & Co., Cantor, and Truist Securities are acting as bookrunners for the offering. Oppenheimer &...

ALACHUA, Fla. and TAMPA, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) — Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced preliminary unaudited fourth quarter and full-year 2023 revenue. Preliminary Unaudited Fourth Quarter and Year-End Performance and Business HighlightsFourth quarter revenue is expected to be approximately $42.7 million, which represents an 18% increase over the fourth-quarter of 2022 driven by solid performance across the product portfolio. Full-year 2023 revenue is expected to be approximately $158.8 million, which represents a 15% increase over the full-year of 2022. This growth is attributed to the effective implementation of sales strategies and the performance of our diverse product portfolio including the launch...

Reported updated data from ongoing Phase 1b trial in kidney transplantation demonstrating tegoprubart treatment successfully prevented kidney transplant rejection and was generally safe and well-tolerated  Dosed first participants in Phase 2 BESTOW trial in kidney transplantation  Tegoprubart dosed in second-ever pig to human xenotransplant procedure IRVINE, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced a summary of 2023 accomplishments and provided guidance for anticipated upcoming 2024 milestones. 2023 Key HighlightsReported updated data from ongoing Phase 1b trial evaluating tegoprubart for prevention of rejection in kidney transplantation. Data from 11 trial participants demonstrated that tegoprubart was generally safe and well-tolerated in patients undergoing...

ALACHUA and TAMPA, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) — Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that President and Chief Executive Officer (CEO) Karen Zaderej plans to retire from the Company by January 2025. The Company’s Board of Directors will retain an executive recruitment firm to manage a search for her successor. When a new CEO is in place, Ms. Zaderej will step down from her executive post and Board duties and continue as a consultant to Axogen for an additional nine months to support the leadership transition and the submission process of the Biologics License Application (BLA) for Avance® Nerve Graft. While the transition is planned to be no later than Jan. 5, 2025, it could occur sooner depending on the timing...

Company Also Announces Departure of Angelo Scopelianos, Ph.D. ALACHUA, Fla. and TAMPA, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) —  Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the promotions of three research and development team members. The promotions are:Erick DeVinney to Chief Innovation Officer Mr. DeVinney joined Axogen in April of 2007 as Director of Clinical Research. During his tenure, he has held positions of progressive responsibility in Clinical Research, Research and Development, Product Development, Medical Education, and Medical Affairs. Mr. DeVinney has more than 16 years of experience driving innovation in peripheral nerve injury diagnosis and repair, including clinical and regulatory development strategies, portfolio...

Financing Led by Leading U.S. Life Sciences-focused Investors PETACH TIKVA, Israel, Jan. 04, 2024 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has entered into a securities purchase agreement for a private placement financing (the “PIPE”) for $16.2 million in gross proceeds priced at the 5-day volume weighted average price as of January 2, 2024 of $4.81 per share. The PIPE syndicate is comprised of new and existing investors, including participation from new U.S. life sciences-focused investors, DAFNA Capital Management and Rosalind Advisors. Under the securities purchase agreement, the investors have agreed to purchase 3,371,312 of the Company’s ordinary shares, no par value per share (the “Ordinary Shares”),...

FITCHBURG, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) — Micron Solutions, Inc. (OTC Pink Markets: MICR) (the “Company”), a diversified contract manufacturing organization, through its wholly-owned subsidiary, Micron Products, Inc., producing highly-engineered, innovative components requiring precision machining and injection molding, announced today that it effected at 4:01 pm ET on January 4, 2024 a 1-for-1,000 reverse stock split (the “Reverse Stock Split”) of the Company’s Common Stock, which was immediately followed effective at 4:02 pm ET by a 1,000 to 1 forward stock split for the Company’s Common Stock (the “Forward Stock Split”, and with the Reverse Stock Split, the “Stock Splits”). The Company’s common stock has been assigned a new CUSIP number of 59511X 204. As a result of the Stock Splits, a stockholder of record owning fewer...

CHARLOTTESVILLE, Va., Jan. 04, 2024 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place in San Francisco on Thursday, January 11, 2024, at 10:30 a.m. PT (1:30 p.m. ET). The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days. About Acumen Pharmaceuticals, Inc. Acumen, headquartered in Charlottesville, VA, with additional offices in Indianapolis, IN and Newton, MA, is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers...